• Consensus Rating: Buy
  • Consensus Price Target: $41.43
  • Forecasted Upside: 75.92%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$23.55
▲ +0.29 (1.25%)

This chart shows the closing price for RGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New REGENXBIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGNX

Analyst Price Target is $41.43
▲ +75.92% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for REGENXBIO in the last 3 months. The average price target is $41.43, with a high forecast of $61.00 and a low forecast of $14.00. The average price target represents a 75.92% upside from the last price of $23.55.

This chart shows the closing price for RGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in REGENXBIO. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/16/2021
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2023SVB LeerinkLower TargetMarket Perform$15.00 ➝ $14.00Low
11/21/2022Morgan StanleyLower TargetOverweight$52.00 ➝ $50.00Low
11/4/2022Chardan CapitalLower TargetBuy$70.00 ➝ $61.00Low
11/4/2022SVB LeerinkBoost TargetMarket Perform$13.00 ➝ $14.00Low
10/4/2022WedbushLower TargetNeutral$32.00 ➝ $28.00Low
10/4/2022Royal Bank of CanadaLower Target$47.00 ➝ $29.00Low
9/9/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $52.00Low
8/10/2022Morgan StanleyLower TargetOverweight$47.00 ➝ $46.00Low
7/11/2022WedbushReiterated RatingHold$29.00N/A
6/23/2022Berenberg BankInitiated CoverageBuy$61.00Low
6/23/2022UBS GroupLower TargetBuy$51.00 ➝ $47.00Low
5/24/2022Morgan StanleyLower TargetOverweight$51.00 ➝ $47.00High
4/11/2022Chardan CapitalReiterated RatingBuyMedium
3/29/2022Chardan CapitalLower Target$90.00 ➝ $76.00High
3/23/2022Morgan StanleyBoost TargetOverweight$50.00 ➝ $51.00Low
3/2/2022SVB LeerinkLower TargetMarket Perform$29.00 ➝ $25.00Medium
2/10/2022SVB LeerinkLower TargetMarket Perform$35.00 ➝ $29.00High
1/28/2022SVB LeerinkLower TargetMarket Perform$43.00 ➝ $35.00High
12/15/2021WedbushInitiated CoverageNeutral$29.00High
11/3/2021Chardan CapitalLower TargetBuy$100.00 ➝ $90.00High
11/3/2021SVB LeerinkLower TargetMarket Perform$44.00 ➝ $43.00High
10/25/2021Roth CapitalBoost TargetBuy$15.00 ➝ $17.00Medium
10/12/2021SVB LeerinkReiterated RatingHoldHigh
9/14/2021Royal Bank of CanadaBoost TargetSector Perform$50.00 ➝ $55.00High
9/14/2021BarclaysBoost TargetOverweight$79.00 ➝ $82.00High
8/10/2021Chardan CapitalReiterated RatingBuy$100.00Low
7/1/2021Chardan CapitalReiterated RatingBuyLow
3/8/2021Morgan StanleyLower TargetOverweight$67.00 ➝ $62.00High
1/20/2021Royal Bank of CanadaBoost TargetNeutral ➝ Sector Perform$42.00 ➝ $50.00High
1/19/2021Morgan StanleyBoost TargetOverweight$51.00 ➝ $67.00Low
1/6/2021SVB LeerinkBoost TargetMarket Perform$34.00 ➝ $37.00N/A
1/6/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$60.00N/A
12/15/2020UBS GroupInitiated CoverageBuy$57.00Low
11/11/2020Morgan StanleyLower TargetOverweight$55.00 ➝ $51.00Medium
11/5/2020SVB LeerinkLower TargetMarket Perform$32.00 ➝ $31.00High
9/24/2020BarclaysLower TargetPositive ➝ Overweight$88.00 ➝ $79.00High
8/25/2020Raymond JamesReiterated RatingBuyHigh
8/14/2020Chardan CapitalReiterated RatingBuy$95.00High
8/10/2020Morgan StanleyLower TargetOverweight$56.00 ➝ $55.00Medium
8/4/2020Chardan CapitalReiterated RatingBuy$100.00Medium
6/25/2020Bank of AmericaInitiated CoverageBuy$60.00High
6/7/2020Chardan CapitalReiterated RatingBuyLow
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$42.00High
5/11/2020Morgan StanleyBoost TargetOverweight$55.00 ➝ $56.00High
4/22/2020Chardan CapitalReiterated RatingBuy$150.00High
3/3/2020Morgan StanleyLower TargetOverweight$58.00 ➝ $55.00High
1/29/2020Chardan CapitalReiterated RatingBuy$150.00Low
1/17/2020Morgan StanleyBoost TargetOverweight$55.00 ➝ $58.00High
12/18/2019Chardan CapitalReiterated RatingBuy$150.00Low
11/11/2019Evercore ISIReiterated RatingBuy$65.00High
10/11/2019Morgan StanleyLower TargetOverweight$85.00 ➝ $59.00Low
9/4/2019Chardan CapitalSet TargetBuy$150.00Low
8/21/2019Chardan CapitalSet TargetBuy$150.00Medium
8/20/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$38.00 ➝ $37.00High
8/7/2019Evercore ISISet TargetBuy$79.00High
7/15/2019Morgan StanleySet TargetBuy$84.00High
6/18/2019Chardan CapitalReiterated RatingBuy ➝ Buy$145.00 ➝ $150.00Medium
6/13/2019Raymond JamesInitiated CoverageOutperform ➝ OutperformHigh
6/5/2019Chardan CapitalReiterated RatingBuy ➝ Buy$127.50 ➝ $145.00Low
2/25/2019Evercore ISIUpgradeIn-Line ➝ Outperform$51.25High
2/5/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$94.00High
1/4/2019Chardan CapitalReiterated RatingBuy$127.50High
12/19/2018Morgan StanleyLower TargetOverweight ➝ Overweight$93.00 ➝ $85.00High
12/18/2018BarclaysBoost TargetOverweight ➝ Overweight$83.00 ➝ $88.00High
12/17/2018Chardan CapitalReiterated RatingBuy ➝ Buy$127.50High
11/27/2018SVB LeerinkInitiated CoverageUnderperform$42.00Low
11/8/2018Bank of AmericaBoost TargetNeutral$76.00 ➝ $84.00High
11/8/2018Raymond JamesSet TargetBuy$96.00High
10/29/2018Raymond JamesReiterated RatingBuyHigh
9/7/2018Raymond JamesBoost TargetOutperform ➝ Outperform$76.00 ➝ $96.00Low
8/13/2018BarclaysBoost TargetOverweight ➝ Overweight$48.00 ➝ $83.00Medium
8/8/2018Chardan CapitalLower TargetBuy$130.00 ➝ $127.50High
7/23/2018Bank of AmericaDowngradeBuy ➝ Neutral$64.00 ➝ $80.00Medium
7/16/2018Chardan CapitalBoost TargetBuy ➝ Buy$90.00 ➝ $130.00High
7/13/2018Morgan StanleyBoost TargetOverweight$37.00 ➝ $92.00Medium
7/10/2018Chardan CapitalBoost TargetBuy ➝ Buy$90.00 ➝ $130.00Medium
6/25/2018Raymond JamesReiterated RatingBuy$76.00High
5/9/2018BarclaysReiterated RatingOverweight ➝ Overweight$38.00 ➝ $48.00High
5/8/2018Raymond JamesSet TargetBuy$45.00High
4/11/2018Raymond JamesSet TargetBuy$45.00Low
4/9/2018Chardan CapitalBoost TargetBuy ➝ Buy$85.00 ➝ $90.00High
3/14/2018Morgan StanleyLower TargetOverweight ➝ Overweight$36.00 ➝ $35.00Low
2/12/2018MizuhoInitiated CoverageNeutral ➝ Neutral$28.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/12/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/10/2022
  • 1 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/10/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
REGENXBIO logo
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Read More

Today's Range

Now: $23.55
Low: $22.93
High: $23.79

50 Day Range

MA: $23.01
Low: $21.76
High: $24.55

52 Week Range

Now: $23.55
Low: $18.69
High: $35.73

Volume

153,868 shs

Average Volume

329,639 shs

Market Capitalization

$1.02 billion

P/E Ratio

15.19

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of REGENXBIO?

The following Wall Street sell-side analysts have issued stock ratings on REGENXBIO in the last twelve months: Berenberg Bank, Chardan Capital, Morgan Stanley, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TheStreet, UBS Group AG, and Wedbush.
View the latest analyst ratings for RGNX.

What is the current price target for REGENXBIO?

7 Wall Street analysts have set twelve-month price targets for REGENXBIO in the last year. Their average twelve-month price target is $41.43, suggesting a possible upside of 75.9%. Chardan Capital has the highest price target set, predicting RGNX will reach $61.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $14.00 for REGENXBIO in the next year.
View the latest price targets for RGNX.

What is the current consensus analyst rating for REGENXBIO?

REGENXBIO currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGNX will outperform the market and that investors should add to their positions of REGENXBIO.
View the latest ratings for RGNX.

What other companies compete with REGENXBIO?

How do I contact REGENXBIO's investor relations team?

REGENXBIO's physical mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 552-8181 and its investor relations email address is [email protected] The official website for REGENXBIO is www.regenxbio.com. Learn More about contacing REGENXBIO investor relations.